Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — BIO International Convention 2015
31 slides from Aethlon Medical's conference presentation, Jun 18, 2015
Slide 1: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ system, t
Slide 2: Aethlon Medical, Inc. BIO International Convention
A e thlon Medical, Inc . BIO INTERNATIONAL CONVENTION JUNE 18 TH , 2015 JIM JOYCE CHAIRMAN, CEO
Slide 3: Therapeutic Biofiltration Devices to Address Life-Threatening Diseases
THERAPEUTIC BIOFILTRATION DEVICES TO ADDRESS LIFE - THREATENING DISEASES
Slide 4: Save Lives
SAVE LIVES
Slide 5: Aethlon Highlights
A e thlon Highlights • Expansive Therapeutic Platform – Lead product provides clinical pathway to address cancer and infectious viral pathogens • DOD Government Contractor (DARPA) – Dialysis - like therapeutics program to treat sepsis
Slide 6: The Aethlon Hemopurifier: Single-Use Removal of Viral Pathogens from Circulation
The A e thlon Hemopurifier® Single - Use Removal of Viral Pathogens from Circulation
Slide 7: Broad-Spectrum Treatment Experience
BROAD - SPECTRUM TREATMENT EXPERIENCE HIV - AIDS Hepatitis - C Ebola
Slide 8: Top Best Inventions of 2014
Top 25 Best Inventions of 2014
Slide 9: The Most Remarkable Advances in Healthcare in 2014
The 11 Most Remarkable Advances in Healthcare in 2014
Slide 10: The Aethlon Hemopurifier: Single-Use Removal of Viral Pathogens from Circulation
The A e thlon Hemopurifier® Single - Use Removal of Viral Pathogens from Circulation
Slide 11: Rethinking the Treatment of Viral Pathogens
Rethinking the Treatment of Viral Pathogens • Rapid virus elimination – Prior to cell and organ infection • Targets viral structure vs. inhibiting replication – Allows broad - spectrum virus capture • Addresses virally shed glycoproteins – To augment and preserve host immune response
Slide 12: Deployed Within the Global Infrastructure of Dialysis & CRRT Machines
DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
Slide 13: Recent Clinical Advancements
Recent Clinical Advancements • Disclosure of HCV treatment results • Reported the treatment of Ebola patient • First clinical protocols approved by FDA – Initiated IDE Feasibility Study in HCV Patients – Ebola Treatment Protocol • Health Canada clinical approval (Ebola)
Slide 14: Ebola Virus as a Therapeutic Model
Ebola Virus as a Therapeutic Model
Slide 15: Reported Ebola Treatment Results, Frankfurt University Hospital
Reported Ebola Treatment Results Frankfurt University Hospital Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)
Slide 16: Hemopurifier Therapy Administration to a Comatose Ebola Patient
Hemopurifier ® therapy administration to a comatose Ebola patient with multiple - organ failure
Slide 17: Ebola Treatment Data Presented at American Society of Nephrology
Ebola Treatment Data Presented By Dr. Helmut Geiger American Society of Nephrology Annual Meeting • 6.5 hour Hemopurifier® therapy administration • Pre - treatment viral load: 400,000 copies/ml • Post - treatment viral load: 1,000 copies/ml • 242 million of Ebola viruses captured • Patient recovered
Slide 18: Dr. Stefan Büttner Holding Hemopurifier After Ebola Treatment
Dr. Stefan Büttner Holding Hemopurifier® After Ebola Treatment
Slide 19: Extracorporeal Virus Elimination for Treatment of Severe Ebola Virus Disease
Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis • Stefan Bü ttner a Benjamin Koch a Olga Dolnik b Markus Eickmann b Tilo Freiwald a Sarah Rudolf a Jü rgen Engel a Stephan Becker b Claudio Ronco c Helmut Geiger
Slide 20: Unmet Needs in Infectious Disease
Unmet Needs in Infectious Disease • Antiviral Drug - R esistance – HIV & HCV • Latent Virus Activation – Immune Suppression • HIV, Organ Transplants, Sepsis • Bioterror & Pandemic Threats – Leading broad - spectrum countermeasure against known and unknown viruses
Slide 21: Bioterror & Pandemic Validations
BIOTERROR & PANDEMIC VALIDATIONS Ebola Pandemic Influenza West Nile Pox Viruses Lassa Dengue
Slide 22: One More Thing
ONE MORE THING
Slide 23: The Aethlon Hemopurifier
The A e thlon Hemopurifier®
Slide 24: Cancer Save Lives
CANCER SAVE LIVES
Slide 25: Tumor-Secreted Exosomes, Extracellular Vesicles or Circulating Microvesicles
Tumor - Secreted Exosomes Extracellular Vesicles or Circulating Microvesicles
Slide 26: Extracellular Vesicles: Emerging Targets for Cancer Therapy
May, 2014 Trends in Molecular Medicine "Extracellular Vesicles: Emerging Targets for Cancer Therapy"
Slide 27: Tumor-Secreted Exosomes: A Significant Unmet Medical Need in Cancer
Tumor - Secreted Exosomes A Significant Unmet Medical Need in Cancer • Trigger apoptosis of immune c ells • Contribute to drug and chemotherapy resistance • Promote angiogenesis • Seed the creation and spread of metastasis • Exosome load correlates with stage of cancer • Transport PD - 1, PDL - 1 ot
Slide 28: An Adjunct Immunotherapeutic Device
An Adjunct Immunotherapeutic Device
Slide 29: Selected Clinical & Corporate Goals
Selected Clinical & Corporate Goals • Complete FDA Approved IDE Study – Prep for pivotal study • Advance HUD submissions – Disease conditions affecting < 4000 per yr. in the U.S. • Complete NASDAQ Up - listing • Launch Immuno - Oncology Programs
Slide 30: Therapeutic Biofiltration Devices to Address Life-Threatening Diseases
THERAPEUTIC BIOFILTRATION DEVICES TO ADDRESS LIFE - THREATENING DISEASES
Slide 31: Save Lives
SAVE LIVES